PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
This study has been completed.
National Institute of Allergy and Infectious Diseases (NIAID)
First Posted: February 23, 2006
Last Update Posted: July 2, 2017
Information provided by:
National Institutes of Health Clinical Center (CC)
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||June 17, 2008|
|Primary Completion Date:||No date given|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One. 2008 Jul 9;3(7):e2636. doi: 10.1371/journal.pone.0002636.